Observational, bi-directional (prospective and retrospective) study for patients with newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021; irrespective of histology

Trial Identifier: D133HR00051
Sponsor: AstraZeneca
Start Date: September 2025
Primary Completion Date: June 2027
Study Completion Date: June 2027
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil Barretos, Brazil
Brazil Belo Horizonte, Brazil
Brazil Brasília, Brazil
Brazil Goiânia, Brazil
Brazil Natal, Brazil
Brazil Porto Alegre, Brazil
Brazil Recife, Brazil
Brazil Rio de Janeiro, Brazil
Brazil Salvador, Brazil
Brazil São Jose dos Campos, Brazil
Brazil São Paulo, Brazil